Portrait Analytics and Third Bridge Partner to Deliver Ai-Driven Investment Research with Human Insight
NEW YORK, NY / ACCESS Newswire / July 29, 2025 / Portrait Analytics, the leading personalized AI-powered investment research platform, today announced a strategic partnership with Third Bridge, a leading global expert network and investment research provider. Embedding Third Bridge's unparalleled library of high-quality expert interviews directly into the Portrait platform will create a one-stop research environment for institutional investors.
This collaboration addresses a growing need in public market investing: combining state-of-the-art AI capabilities with powerful qualitative insights from trusted experts. Instead of switching between siloed tools or stitching together AI workflows manually, investors can now leverage AI to seamlessly surface real-time expert perspectives at the moment they're discovering, researching, and monitoring an investment thesis.
"Investors are excited by AI's potential to add leverage to the research process, but are struggling to integrate this technology with critical data sources," said David Plon, CEO and co-founder of Portrait Analytics. "Integrating Third Bridge's extensive library of expert insights and company intelligence into our leading AI platform is a major step towards helping our users fully unlock the value of this research for creative idea generation and thesis development."
This partnership benefits institutional investors, particularly hedge funds and asset managers who rely on expert interviews as part of their research process. Third Bridge subscribers on the Portrait platform can now instantly leverage the collective insights from thousands of experts through Portrait's deep research workflows. For instance, an analyst researching GLP-1s can now leverage Portrait to analyze thousands of expert conversations about downstream impacts on medical devices, food companies, and insurers, uncovering non-obvious investment opportunities.
"Portrait's platform is the perfect environment to unlock even more value from our trusted library of expert insights," said Mike Grubert, Managing Director at Third Bridge, "This collaboration underscores our commitment to providing the world's decision makers with access to the high-quality insights they need, whenever and wherever they need them. Together, we're giving our mutual clients a faster, smarter way to conduct due diligence and develop differentiated insight into investment opportunities."
ABOUT PORTRAIT ANALYTICS:
Portrait Analytics is a personalized AI-powered investment research platform that supports critical public market workflows across idea generation, context-building, and thesis monitoring. Built by former buy-side analysts, Portrait is headquartered in New York with a presence across the U.S. and Europe. Learn more at https://www.portraitanalytics.ai.
ABOUT THIRD BRIDGE:
Third Bridge is a global investment research business, providing investors and business leaders with access to the unique expert insights they need to accelerate and improve their decision-making. Founded in 2007, it has 1,500+ employees who serve the world's top private equity funds, hedge funds, mutual funds, and management consulting firms. Learn more at: www.thirdbridge.com.
MEDIA CONTACT: Lauren Gill, MAG PR at lauren@mooringadvisorygroup.com.
SOURCE: Portrait Analytics
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Noodles, GoodRx, Micron, Custom Truck One Source, and CarMax Shares Are Falling, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this trend is that much of the recent market gains were concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed. Despite the downturn, some analysts viewed this as an opportunity to own some of the "Core AI winners." Dan Ives of Wedbush Securities commented, "In our view, the tech bull cycle will be well intact for at least another 2-3 years, given the trillions being spent on AI infrastructure/software/chips/power/apps looking ahead. This remains our tech playbook and investor roadmap." Additionally, mixed earnings reports from retailers, such as Target, have added to the market's weakness. Investors are closely monitoring these reports for insights into the broader economic health and the potential impact of new tariffs on inflation. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Modern Fast Food company Noodles (NASDAQ:NDLS) fell 5.8%. Is now the time to buy Noodles? Access our full analysis report here, it's free. Healthcare Technology for Patients company GoodRx (NASDAQ:GDRX) fell 7.7%. Is now the time to buy GoodRx? Access our full analysis report here, it's free. Memory Semiconductors company Micron (NASDAQ:MU) fell 5.8%. Is now the time to buy Micron? Access our full analysis report here, it's free. Specialty Equipment Distributors company Custom Truck One Source (NYSE:CTOS) fell 4.9%. Is now the time to buy Custom Truck One Source? Access our full analysis report here, it's free. Vehicle Retailer company CarMax (NYSE:KMX) fell 4.3%. Is now the time to buy CarMax? Access our full analysis report here, it's free. Zooming In On GoodRx (GDRX) GoodRx's shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 40.2% on the news that the company announced a collaboration with pharmaceutical giant Novo Nordisk to offer the popular medications Ozempic and Wegovy for $499 per month to eligible self-paying customers. This landmark collaboration makes the popular GLP-1 medications—used for type 2 diabetes (Ozempic) and weight loss (Wegovy)—available at a significantly lower cost to those who lack adequate insurance coverage. According to the announcement, this marks the first time Ozempic has been offered at this self-pay price point. The offer is effective immediately and available through the GoodRx platform at over 70,000 retail pharmacies nationwide. Investors reacted positively, viewing the strategic partnership as a pivotal move that could substantially expand GoodRx's market reach and user base by capitalizing on the high-demand therapeutic category. GoodRx is down 3.6% since the beginning of the year, and at $4.40 per share, it is trading 48.8% below its 52-week high of $8.59 from August 2024. Investors who bought $1,000 worth of GoodRx's shares at the IPO in September 2020 would now be looking at an investment worth $87.03. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
10 hours ago
- Yahoo
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
CNBC
15 hours ago
- CNBC
10 things to watch in the stock market Wednesday including TJX's surge and new Target CEO
The Club's 10 things to watch Wednesday, Aug. 20 — Today's newsletter was written by Investing Club editor Kevin Stankiewicz. 1. Wall Street was set to open slightly lower today after the S & P 500 closed lower yesterday for the third session in a row. Investors were parsing the latest retail earnings this morning. They were also looking ahead to this afternoon's release of the minutes from the Federal Reserve's July meeting — two days before Fed Chairman Jerome Powell addresses the Jackson Hole central bank confab Friday. 2. Shares of TJ Maxx parent TJX Companies are rallying to a new all-time high after second-quarter earnings results beat expectations. Same-store sales were also better than what the Street was expecting. TJX also raised its full-year guide despite tariff headwinds. Consumers want value, and that's what TJX's off-price chains deliver. 3. Target shares tumbled nearly 11% on earnings yet again after the struggling retailer reported another quarter of same-store sales declines and reiterated its full-year outlook. It also announced that Chief Operating Officer Michael Fiddelke will replace longtime CEO Brian Cornell in February. 4. Shares of Lowe's added 3% on the back of better-than-expected quarterly sales and revenue , along with a slight increase to its full-year sales outlook. The home improvement retailer also announced plans to buy drywall and insulation distributor Foundation Building Materials for $8.8 billion. It's a move that mirrors Club name Home Depot's two recent acquisitions to better serve professional customers. 5. McDonald's is cutting the price of combo meals after the fast-food chain was able to convince its franchisees to go along with the plan, The Wall Street Journal reported . It's part of an effort to win back customers who have shied away from the chain in recent years due to rising prices. 6. Club name Amazon's auto sales platform is adding used cars from Hertz , sending shares of the car-rental provider up 10%. Amazon's stock wasn't moving much, unsurprisingly, given that Amazon Autos is a tiny part of the overall company. But with shares of Carvana and Carmax down on the news, investors clearly see the potential for Amazon to grow it. 7. The national average rate on a 30-year fixed-rate mortgage ticked up to 6.68% from last week's 6.67%, and home loan demand stalled. After last week's 23% surge in refinancing applications, refis fell 3% this week. Purchase apps rose 0.1% after last week's 1% increase, according to the latest data from the Mortgage Bankers Association . 8. The FDA approved the first-ever glucose monitoring system specifically for weight loss. The startup Signos makes the system, which uses AI and an off-the-shelf continuous glucose monitor from Dexcom . It can be used as another tool by people taking the GLP-1 drugs from Club name Eli Lilly and Novo Nordisk . But, anyone who wants to lose weight can use the system to help them on their journey. 9. Club name Honeywell is buying a trio of utility software programs from SparkMeter. While these are small deals for Honeywell, the strategic rationale is about enhancing its exposure to growing electricity demand, thanks largely to AI computing. 10. Microsoft will be "an important partner for years to come," OpenAI finance chief Sarah Friar said this morning on CNBC's "Squawk Box." With questions about what OpenAI's push for independence could mean for Club stock Microsoft, Friar's comments are notable. Their evolving and reportedly tense relationship is one of the biggest stories in tech and AI . Sign up for my Top 10 Morning Thoughts on the Market email newsletter for free (See here for a full list of the stocks at Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
